Jeff Yass’s NRX Pharmaceuticals NRXP Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$35.6K Buy
+12,197
New +$43.3K ﹤0.01% 12995
2025
Q1
– Sell
-82,152
Closed -$231K – 13143
2024
Q4
$181K Buy
+82,152
New +$110K ﹤0.01% 10838
2023
Q4
– Sell
-1,410
Closed -$4.66K – 12999
2023
Q3
$3.67K Buy
+1,410
New +$4.69K ﹤0.01% 11813
2023
Q2
– Sell
-8,062
Closed -$48.5K – 12801
2023
Q1
$53.1K Buy
8,062
+5,289
+191% +$53.6K ﹤0.01% 11677
2022
Q4
$30.8K Sell
2,773
-1,536
-36% -$15.5K ﹤0.01% 11615
2022
Q3
$32K Sell
4,309
-4,448
-51% -$30K ﹤0.01% 12424
2022
Q2
$53K Buy
8,757
+5,696
+186% +$74.8K ﹤0.01% 11948
2022
Q1
$75K Sell
3,061
-4,835
-61% -$157K ﹤0.01% 12091
2021
Q4
$377K Buy
7,896
+2,363
+43% +$171K ﹤0.01% 9931
2021
Q3
$513K Buy
+5,533
New +$720K ﹤0.01% 9339
2019
Q3
– Sell
-1,147
Closed -$120K – 10622
2019
Q2
$120K Buy
+1,147
New +$119K ﹤0.01% 9519

Other funds holding NRXP

Jeff Yass's NRXP Position: Q3 2026 in Review

Jeff Yass opened a new position in NRX Pharmaceuticals (NRXP) in Q3 2026: 12,197 shares worth $35.6K. The stake represents ﹤0.01% of the portfolio and ranks #12995 among its holdings. This is a return to the name: Jeff Yass previously reported a position in NRXP as recently as Q4 2024.

Jeff Yass first reported a position in NRXP in Q2 2019 and has held it in 11 quarters since. The position peaked at $513K in Q3 2021. 50 funds tracked by Wall St. Rank hold NRXP as of Q3 2026.

  • Jeff Yass held 12,197 shares of NRX Pharmaceuticals worth $35.6K as of Q3 2026.
  • NRX Pharmaceuticals was a new Jeff Yass position in Q3 2026.
  • NRX Pharmaceuticals made up ﹤0.01% of Jeff Yass's portfolio in Q3 2026, its #12995 holding.
  • Jeff Yass first reported a position in NRX Pharmaceuticals in Q2 2019 and has held it in 11 quarters since.
  • Jeff Yass's NRX Pharmaceuticals position peaked at $513K in Q3 2021.
  • 50 funds tracked by Wall St. Rank held NRX Pharmaceuticals as of Q3 2026.

Based on Susquehanna International Group's 13F filing for Q3 2026, filed 16 Nov 2026.